LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), the global leader in food and environment testing, announces that it has acquired Ahma Ymparisto Oy (“Ahma”), the second-largest environment testing laboratory in Finland.
Founded in 1977, Ahma has built a solid reputation in the domestic environment testing market, with a strong footprint in the northern and western parts of the country, and with some strong competences in the fields of water, hydrobiology and bio-fuels testing in particular. The company employs 104 staff across its 3 main sites, and generated revenues in excess of EUR 7m in 2016.
Ahma’s geographical footprint and test portfolio complements the Group’s strong presence in the south of the country, obtained following the recent acquisition of Ramboll Group’s laboratories. The acquisition should therefore consolidate the Group’s leadership in the Finnish environment testing market.
Comment from Antti Kuivalainen, Chairman of the Board of Ahma Insinöörit Oy: “I am very proud that Ahma Environment found a new home within the Eurofins family. This transaction will create a superior environmental testing and research organisation in Finland as well as in the whole Nordics.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Ahma illustrates Eurofins’ strategy of consolidating and continually strengthening our leading operational footprint. We are committed to supporting Ahma’s further development by giving them access to the full range of capabilities of the Group. Together with the recently-acquired laboratories from Ramboll, we look forward to supporting their respective operations and further developing their capabilities to continue providing customers in Finland with the highest level of analytical service.”
For more information, please visit www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 27,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.